№ lp_2_3_11471
File format: docx
Character count: 3596
File size: 27 KB
This is a table detailing the antibodies used for various cell markers and cytokines in an immunology research study.
Year:
Not specified
Region / city:
Not specified
Topic:
Antibody usage in immunology study
Document type:
Table
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers in immunology
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Region / City:
United States
Topic:
Pharmaceutical naming and regulatory processes
Document type:
Application form
Organization / Institution:
United States Adopted Names Council, American Medical Association
Target audience:
Pharmaceutical companies, researchers, regulatory authorities
Year:
2025
Region / City:
Northern Victoria
Topic:
Epidemiology, Infectious Diseases, Public Health
Document Type:
Research Study
Author:
Marie Heloury, Joshua Szanyi, Maxwell Braddick, Alexander Fidao, Madeleine J Marsland, Tilda N Thomson, Mitch Batty, Suellen Nicholson, Theo Karapanagiotidis, Kylie Carville, Anna-Jane Glynn-Robinson, Chuan Kok Lim, Naveen Tenneti, Anthony Zheng, William Cross, Jim Black, Helen O’Brien
Target Audience:
Researchers, Public Health Officials, Epidemiologists
Period of Validity:
2023–2024
Date of Approval:
2025-03-25
Date of Changes:
Not specified
Year:
2010
Region / City:
N/A
Subject:
Biomedical Research, Cell Biology, Molecular Biology
Document Type:
Research Methods Supplement
Author:
N/A
Target Audience:
Researchers, Scientists in Biomedical Fields
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2024
Region / city:
India
Topic:
Immunology, Biotechnology
Document type:
Book Chapter
Institution:
Tomo Riba Institute of Health & Medical Sciences (TRIHMS)
Author:
Ashmita Banik
Target audience:
Scientific community, Researchers in Biotechnology and Immunology
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Section:
Supplemental Methods
Field:
Immunology and Hematologic Malignancies
Experimental focus:
B7-H3 CAR-T cells in acute myeloid leukemia (AML)
Monoclonal antibodies:
Anti-human CD markers and related reagents for flow cytometry
Suppliers:
Becton-Dickinson (BD) Biosciences; Miltenyi Biotec; BioLegend; Jackson ImmunoResearch Labs
Cell lines:
THP1; U937; HL-60; Kasumi-1; OCI-AML2; OCI-AML3
Primary samples:
DFAM-6855; CBAM-44728 from Public Repository of Xenografts (PRoXe), Dana-Farber Cancer Institute
Biological material:
Primary AML blasts; donor PBMCs; buffy coats from healthy volunteers
Vector system:
SFG retroviral vector with MoMLV gag-pol and RD114 envelope
Transduction method:
Retronectin-coated plates with retroviral supernatant
Cell expansion cytokines:
IL7; IL15
Statistical methods:
Mann Whitney test; one-way ANOVA with Holm-Sidak adjustment; Chi-square test
Software:
Prism version 8 (GraphPad)
Sample origin:
Bone marrow and peripheral blood from AML patients
Animal model:
NSG mice for in vivo expansion of xenografts
Culture conditions:
RPMI-1640 medium with fetal bovine serum, L-glutamine, penicillin, and streptomycin
Year:
2026
Region / City:
Not specified
Subject:
Clinical diagnostics, virology
Document Type:
In vitro diagnostic test instructions
Organization:
ZEUS Scientific, Inc.
Author:
Not specified
Target Audience:
Laboratory personnel
Period of Use:
Ongoing
Date of Issue:
2026
Safety Precautions:
Biosafety Level 2, toxic and irritant reagents handling instructions included
Components:
Microplate strips, conjugate, controls, calibrator, diluent, substrate, stop solution, wash buffer
Intended Sample:
Human serum
Test Principle:
ELISA detection of IgG antibodies to EBV Nuclear Antigen 1 (EBNA-1)
Assay Procedure:
Three-step incubation with antigen-coated wells, conjugate, and substrate followed by photometric measurement
Study title:
Prevalence of Pathogenic Antibodies in Psychosis 2 (PPiP2)
Principal Investigator:
Local PPiP2 researcher
Participant study ID:
[ID]
Date:
[Date]
Version:
[Version]
Year:
[Year]
Region / City:
[Region or city if mentioned]
Topic:
Medical Research, Psychiatric Studies
Document Type:
Consent Form
Institution:
University of Oxford
Author:
[Author(s) if available]
Target Audience:
Research Participants, Medical Professionals
Study Period:
[Study Period if mentioned]
Approval Date:
[Date of approval if mentioned]
Amendment Date:
[Date of amendments if mentioned]
Year:
Not specified
Region / city:
Not specified
Topic:
Environmental, Social, Economic Impacts of Chemical & Pharmaceutical Products
Document Type:
Environmental/Social/Economic Impact Analysis
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Not specified
Effective Date:
Not specified
Date of Changes:
Not specified
Contextual description:
Environmental, social, and economic impact analysis of chemical and pharmaceutical products.
Year:
2026
Region / City:
Not specified
Field:
Immunology / Molecular Biology
Document Type:
Supplementary Table
Institution:
Not specified
Authors:
Not specified
Target Audience:
Researchers in immunology and molecular biology
Reagents Included:
Antibodies, Chemicals, Peptides, Recombinant Proteins, Additional Reagents, Critical Commercial Assays
Organism:
Mouse
Experimental Context:
T cell characterization and immunological assays
Source:
Multiple commercial suppliers listed for each reagent
Note:
Year
Year:
2021
Institution:
Niigata University
Type of document:
Research protocol and experimental report
Target molecules:
GlyR (GLRA1), GABABR (GABBR1), NMDAR, AMPAR, LGI1, GABAAR, CASPR2
Methodology:
PCR amplification, In-Fusion HD cloning, cell-based assay (CBA), fluorescence microscopy
Sample type:
Serum, cerebrospinal fluid (CSF)
Patient group:
55 SPS patients, neurodegenerative disorder controls, healthy volunteers
Assay validation:
Control samples tested negative
Reference studies:
Dalakas MC et al., Tanaka K et al., Nakane S et al., Nakanishi T et al., Maeda K et al., Iizuka T et al., Nanaura H et al.
Year:
2024
Region / City:
Europe
Topic:
Preclinical drug safety assessment
Institution:
Master’s programme, Drug Innovation
Author:
Benedetta Boscolo Todaro
Supervisors:
Hsiao-Tzu Chien, Marieke de Bruin, Peter Van Meer
Target audience:
Regulatory scientists, pharmacologists
Study period:
October 2024 – April 2025
Data analyzed:
42 monoclonal antibodies submitted for EMA approval (2017–2024)
Methodology:
Weight-of-evidence approach, literature review, short-term toxicity studies
Ethical considerations:
Reduction of animal testing, alignment with 3Rs principles
Year:
Not provided
Region / City:
Not specified
Topic:
Research ethics, manuscript submission
Document type:
Template
Author:
Not specified
Target audience:
Authors submitting research articles
Period of validity:
Not provided
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Global
Topic:
Transboundary river research, Natural Language Processing, Named Entity Recognition, Python
Document type:
Research methodology
Organization / Institution:
None mentioned
Author:
Sahana et al.
Target audience:
Researchers in the field of natural language processing and transboundary river studies
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / City:
N/A
Topic:
Education, Learning Disabilities
Document Type:
Report
Organization:
N/A
Author:
N/A
Target Audience:
Educators, Special Education Teachers
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2023
Region / City:
Georgia
Topic:
Drug management, Isoflurane usage
Document Type:
Instructional form
Organization / Institution:
Georgia Board of Pharmacy
Author:
Georgia Board of Pharmacy
Target Audience:
Registrants (licensed distributors, manufacturers, and dispensers of dangerous drugs)
Effective Period:
2023 - ongoing
Approval Date:
N/A
Modification Date:
N/A
Note:
Study Summary 1.1 Please provide a brief summary of the study in the table below. A complete description of the study with detailed information should be provided in the body of the protocol. For sections not applicable to the study, mark them as N/A. Study Title Study Design Primary Objective/Purpose Secondary Objective(s)/Purposes Research Intervention(s) ClinicalTrials.gov NCT # Study Population Sample Size Study Duration for individual subjects Study Specific Abbreviations/ Definitions
Background 3.1 Provide the scientific or scholarly background for, rationale for, and significance of the research based on the existing literature and how will it add to existing knowledge. :
this section should be limited to only information directly related to the research questions and objectives. Do not include your full dissertation proposal. 3.2 Describe any relevant preliminary data (e.g. pilot data).
Procedures Involved 5.1 Describe and explain the study design. 5.2 Please select the methods that will be employed in this study (select all that apply):
☐ Audio/Video Recording ☐ Psychophysiological Recording ☐ Behavioral Interventions ☐ Record Review - Educational ☐ Behavioral Observations and Experimentations ☐ Record Review - Employee ☐ Deception ☐ Record Review- Medical ☐ Focus Groups ☐ Record Review - Other ☐ Interviews ☐ Specimen Collection or Analysis ☐ Investigational Medical Device – (e.g. Medical Mobile Applications) ☐ Surveys and/or Questionnaires ☐Psychometric Testing ☐ Other Social-Behavioral Procedures Provide a description of all research procedures being performed and when they are performed. (Upload any surveys, questionnaires, interview scripts, focus group scripts, debriefing scripts, psychometric tests, stimulus materials, intervention manuals, and data collection forms on the Local Site Documents page in the IRB application.) 5.3 Describe the procedures or interventions that are going to be conducted as part of the research project, but that would have been conducted anyway, even if the research was not occurring (i.e. standard of care procedures, activities that would occur in a classroom). 5.4 Describe the procedures performed to lessen the probability or magnitude of risks of items selected in 5.2.5. 5 If accessing or collecting existing data, describe: The data that will be collected during the study (e.g. demographics, medical history, etc.). Attach the data capture sheet(s) on the Local Site Documents page in the IRB application. How the data will be obtained, including how you have the authority to access the data. The source or location of the data (e.g. USF Epic, TGH Epic, Hillsborough County School records, CANVAS records, publicly available databases, etc.). 5.6 If collecting and/or analyzing biological specimens, describe: How the biological specimens will be or have been collected. How the biological specimens will be stored. How long the biological specimens will be stored. How the biological specimens will be used. The laboratories that will be used. Whether the collected biological specimens will undergo genetic testing. If so, indicate if this study is part of a Genome Wide Association Study (GWAS) and whether the data will be forwarded to the NIH dbGaP. 5.7 If there are plans for long-term follow-up (once all research related procedures are complete), what data will be collected during this period.
Data and Specimen Storage for Future Research 6.1 If data or specimens will be banked for future research studies, describe where the data or specimens will be stored, how long it/they will b:
the process to request a release, approvals required for release, who can obtain data or specimens, and the data to be provided with specimens.